Specifically, in the field of cancer immunotherapy, a major focus is on developing peptide and small-molecule modulators that target critical immune checkpoint proteins such as PD-1 and PD-L1, thereby unleashing the body’s own anti-tumor immune response [12]. The gene discussed is PDCD1; the disease is neoplasm.